Razelle Kurzrock/froedtert.com
Aug 29, 2025, 19:11
Razelle Kurzrock: HER2 Testing – Small Cost, Big Impact
Razelle Kurzrock, Founding Director of Michels Rare Cancers Research Laboratories at the Medical College of Wisconsin and Co-Founder and Board Member at CureMatch, shared a post on X:
“We seem to be debating whether it’s worthwhile to do a cheap HER2 IHC if HER2 is rare. Biopsies have an average of 5-12 IHCs done routinely. No one questions that.
If you miss the HER2 diagnosis, the patient can be treated with ineffective therapy, which presumably saves money.”
More posts featuring Razelle Kurzrock.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 29, 2025, 19:11
Aug 29, 2025, 18:53
Aug 29, 2025, 18:05
Aug 29, 2025, 17:46
Aug 29, 2025, 17:20
Aug 29, 2025, 17:01
Aug 29, 2025, 16:46